Table 1

Clinicopathological information about patients with Crohn’s disease (CD) or ulcerative colitis (UC)

Patients
No	Age (y)	Sex	Medication	Diagnosis	Duration (y)	Specimen site	Local inflammation^1-150
1	25	F	Sulphasalazine 3 g	CD	11	Ileum	3+
2	22	F	Prednisolone 15 mg, mesalazine 2 g	CD	6	Ileum	3+
3	27	F	Mesalazine 750 mg	CD	10	Ileum	0
4	26	M	None	CD	9	Ileum	3+
5	46	M	Mesalazine 1 g	CD	13	Ileum	2+
6	30	M	Prednisolone 12.5 mg, mesalazine 1 g	CD	<1	Ileum	3+
7	38	F	Prednisolone 15 mg	CD	1	Ileum	0
8	29	M	Prednisolone 20 mg	CD	14	Duodenum	0
9	43	M	Prednisolone 12.5 mg, mesalazine 1 g	CD	18	Ileum	2+
10	27	F	Prednisolone 10 mg, azathioprine 100 mg, metronidrazole 1600 mg	CD	3	Colon	2+
11	24	F	None	CD	5	Colon	3+
12	38	F	Methylprednisolone 100 mg, azathioprine 100 mg	CD	6	Colon	3+
13	45	F	None	CD	8	Colon	3+
14	26	F	Methylprednisolone 60 mg	CD	3	Colon	3+
15	71	M	Prednisolone 10 mg, mesalazine 1.5 mg	CD	4	Rectum	2+
16	36	F	None	CD	9	Sigmoid colon	2+
17	24	F	Prednisolone 10 mg	CD	22	Ascending colon	1+
18	22	M	Prednisolone 25 mg, azathioprine 100 mg, sulphasalazine 2 g	CD	6	Rectum	2+
19	45	M	Sulphasalazine 3 g	UC	25	Colon	3+
20	35	F	Prednisolone 60 mg, cyclosporin 800 mg, sulphasalazine 2 g	UC	< 1	Colon	3+
21	32	F	None	UC	14	Colon	3+
22	48	F	Prednisolone 7.5 mg	UC	4	Rectum	3+
23	41	M	Hydrocortisone 40 mg	UC	23	Colon	3+
24	45	M	Sulphasalazine 3 g	UC	25	Colon	3+

↵1-150 Disease activity graded according to: 0, normal mucosa; 1+, mild inflammation, some crypt abscesses, slight structural changes; 2+, moderate active inflammation, several crypt abscesses, moderate structural changes; and 3, severe active inflammation, superficial erosions, and notable structural changes.